Abemaciclib trials for Breast cancer

All Abemaciclib trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Abemaciclib for Breast cancer

• A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
  NCT06188520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
  NCT05708235 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
  NCT05766410 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 2 locations
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
  NCT04802759 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 32 locations
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
  NCT06678269 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
  NCT05307705 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 50 locations
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 359 locations
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 352 locations
• A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
  NCT07100106 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
  NCT07112053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
  NCT04523857 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
  NCT04305834 · Phase: Phase 2 · Ages: 70 Years and older · Sex: All (male and female) · 6 locations
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
  NCT05524584 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
  NCT06365788 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 6 locations
• ETHAN - ET for Male BC
  NCT05501704 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 9 locations
• Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
  NCT05891093 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 15 locations
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
  NCT05768139 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
  NCT06179303 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
  NCT05933395 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
  NCT07191717 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
  NCT06805812 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
  NCT06139107 · Phase: Phase 1 · Ages: 60 Years and older · Sex: Female · 4 locations
• SR & Abemaciclib With/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
  NCT04923542 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
  NCT06380751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 302 locations
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
  NCT06409390 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
  NCT04614194 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
  NCT05386108 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 86 locations
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
  NCT05372640 · Phase: Phase 1 · Ages: 12 Years and older · Sex: All (male and female) · 7 locations
• VS-6766+Abema+Fulv in Met HR+/HER- BC
  NCT05608252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations

Common questions

How many trials study Abemaciclib for Breast cancer?

34 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.